Astion Pharma A/S

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

ASF1057
ASF1057 is an investigational therapeutic targeting immune or inflammatory pathways in development by Astion Pharma.

Phase 2 pipeline

ASF 1096 0.5 % cream · Dermatology
ASF 1096 0.5% cream is a topical corticosteroid used to reduce inflammation and itching in various skin conditions.
ASF 1096 0.5 % cream applied twice daily · Dermatology
ASF 1096 is a topical cream formulation with an unknown mechanism of action in Phase 2 development by Astion Pharma A/S.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Astion Pharma A/S portfolio CI brief
Astion Pharma A/S pipeline updates RSS

Frequently asked questions about Astion Pharma A/S

What is Astion Pharma A/S's pipeline?

Astion Pharma A/S has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include ASF1057.

Sector hub: All tracked pharma companies